Posted on 04/08/2010 in Pharmaceutical Company Product News Daiichi Sankyo has announced plans to progress its non-small cell lung cancer drug ARQ 197 to phase III testing in a new clinical trial.
The company, in association with development partner ArQule, is to compare the efficacy of a combination of erlotinib plus ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, against erlotinib plus placebo.
It is proceeding with this trial based on positive findings from a recently concluded phase II study, in which the drug demonstrated promising results in terms of progression-free survival among patients.
Dr Kazunori Hirokawa, global head of research and development at Daiichi Sankyo, said: "Based on these results, we are developing plans to support a phase III clinical programme and bring new hope to patients with this disease."
ArQule and Daiichi Sankyo have been working together on developing ARQ 197 since 2008.
Earlier this week, Daiichi Sankyo announced that it will create a new joint venture with the Kitasato Institute in order to research and develop new vaccines. Other news stories from 04/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
